Atai Life Sciences
Preço: 3.92Empresa e modelo de negócios
Atai Life Sciences is a biotechnology company focused on developing innovative treatments for mental health disorders. Its core products include psychedelic compounds and therapies aimed at addressing conditions such as depression and anxiety. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations, licensing agreements, and potential future product sales.
Perfil de investimento
The investment profile of Atai Life Sciences is more aligned with growth investors, given its focus on developing novel therapies and the potential for significant market impact. However, the company's current financial performance indicates higher risk, making it less suitable for conservative investors seeking stable returns. The stock may appeal to those with a medium to long-term investment horizon, as it navigates the complexities of drug development and regulatory approval.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -3.00 Risco
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -10.5% ↓
- Surpresa de EPS
- 27.3% melhor que o esperado
- Volatilidade 20d
- 4.3% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-05 02:55 | Manter | Vender | Weak fundamentals and high risk limit upside potential. |
| 2026-05-28 02:35 | Vender | Manter | Weak fundamentals and high risk limit upside potential. |
| 2026-05-20 02:35 | Manter | Vender | scenario_deterioration |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-04-20 11:57 | Canaccord Genuity | Preço-alvo elevado | 14 → 15 | 5.2 |
| 2026-03-27 08:52 | Deutsche Bank | Atualizar | — → 12 | 3.35 |
| 2026-03-06 20:37 | Jefferies | Atualizar | — → 10 | 3.39 |
Nada ainda